Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Eli Lilly and Company
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has an HbA1c between 7.0% and 10.0%, inclusive.
Subject has a body mass index (BMI) \>25 kg/m\^2 and \<50 kg/m\^2.
Subject is on a stable dose of metformin or metformin plus a thiazolidinedione.
You may not be if
Subject has been treated with any of the following medications: \*exogenous insulin for more than 1 week within 3 months of screening, \*sulfonylureas or meglitinides within 2 months of screening, \*alpha-glucosidase inhibitors within 2 months of screening, \*pramlintide acetate injection within 2 months of screening.
Subject has received exenatide, GLP-1 analogs, DPP-IV inhibitors, or has participated in this study previously.
Clareo Health | Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes
